Deucravacitinib (TYK2) in PsA from POETYK trials Improved ACR20 at wk16 (NNT ~5), less benefit for ACR70 (NNT ~20) Steady improvements during open label extension (all pts received drug) Would expect approval for PsA soon... where will this fit in your approach? @RheumNow https://t.co/325h2hf0AE